It is easy to focus on the glorious scientific discovery and wondrous innovation that cut waves along the surface of pharma performance; it’s a bit harder to reach into the depths and find transformation in the financial weeds.
A descent into the tendrils of balance sheets, trading matrices and international policy can require the need for decompression before emerging with a clear idea of where and how they influence markets.
But the complex disciplines of pricing, global deals and access thresholds are having their moment in the sun as the biggest catch of the season, with market-shaping changes that are creating significant ripples in 2026.
The confluence of the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) dropping from 22.9% to 14.5%, the 2026 Statutory Scheme headline payment being cut from 24.3% to 16.5%, the UK-US tariff and investment deal and the rise of NICE cost-effectiveness thresholds has created a positive climate for investment, innovation and, critically, patient access to therapies.
There are detractors who warn that the UK will be hit with a huge bill when the three-year 0% tariffs on pharmaceutical exports to the US ends, but the incentive to launch innovative medicines and supercharge the mechanics of getting them to patients has been given a rare boost.
Read the article in full here.
Danny Buckland is a freelance journalist specialising in the pharmaceutical industry